Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis.
Effects of prolonged fasting on fatigue and quality of life in patients with multiple sclerosis.
Expression Profile of Long Non-Coding RNAs in Serum of Patients with Multiple Sclerosis.
Laquinimod, an upcoming oral immunomodulatory agent for treatment of multiple sclerosis.
Time matters - Acute stress response and glucocorticoid sensitivity in early multiple sclerosis.
Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: No.
Curbing Inflammation in Multiple Sclerosis and Endometriosis: Should Mast Cells Be Targeted?
A meta-analysis of interaction between Epstein-Barr virus and HLA-DRB1*1501 on risk of multiple sclerosis.
Self-rated health in women prior to clinical onset of multiple sclerosis: A study within the Danish National Birth Cohort.
Robotic gait rehabilitation and substitution devices in neurological disorders: where are we now?
Gamma Knife rhizotomy-induced histopathology in multiple sclerosis-related trigeminal neuralgia.
Dimethyl fumarate for treating relapsing multiple sclerosis.
A method for estimating and removing streaking artifacts in quantitative susceptibility mapping.
Memory impairment in multiple sclerosis: Relevance of hippocampal activation and hippocampal connectivity.
Myelin basic protein is a glial microtubule-associated protein - Characterization of binding domains, kinetics of polymerization, and regulation by phosphorylation and a lipidic environment.
Biotinidase deficiency mimicking neuromyelitis optica: Initially exhibiting symptoms in adulthood.
Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients.
Objectively Quantified Physical Activity in Persons with Multiple Sclerosis.
Relative contribution of cognitive and physical disability components to quality of life in MS.
Towards Establishing a Multiple Sclerosis Biobank in Jordan.
[New and future treatments for neurological disorders--knowledge essential to daily clinics and future prospects. Topics: 9. Therapeutic progress in multiple sclerosis and neuromyelitis optica].
Bladder management in multiple sclerosis.
Clinical and imaging findings in three patients with advanced inflammatory demyelinating polyradiculoneuropathy associated with nerve root hypertrophy.
Spasticity in multiple sclerosis: Associations with impairments and overall quality of life.
Updated views on autologous hematopoietic stem cell transplantation for treatment of multiple sclerosis.
Pages
« first
‹ previous
…
625
626
627
628
629
630
631
632
633
…
next ›
last »